Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSichuan University
About this trial
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer
Eligibility criteria
Qualifiers
Age ≥18 years and age ≤75 years.
ECOG score 0-1.
Patients with histologically confirmed pancreatic ductal adenocarcinoma, R0 resection, stage I-III, not receiving neoadjuvant therapy.
Patients of childbearing potential must take appropriate precautions prior to enrollment and during the study.
Disqualifiers
Received antitumor chemotherapy, radiation therapy, or immunotherapy within 2 weeks prior to first vaccination.
The patient has a history of other tumors, except for cervical cancer in situ, treated squamous cell carcinoma or urothelial tumors (Ta and TIS), or other malignancies that have been treated with curative intent (at least 5 years prior to enrollment).
Uncontrollable comorbidities, including but not limited to active bacterial or fungal infections, symptomatic congestive heart failure, unstable angina, arrhythmias.
HIV infection or active hepatitis B (HBV DNA≥500IU/ml), hepatitis C.
Trial design
Treatments tested in this trial
- Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
Treatment groups
43 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov